1.3 CKD Etiology, KDIGO Staging & Progression Risk

CKD Etiology, KDIGO Staging & Progression Risk

Chronic Kidney Disease (CKD) represents a major public health burden, affecting about 14% of U.S. adults (roughly 35.5 million people in recent CDC estimates) and more than 850 million people worldwide. The progressive loss of functional nephrons impairs fluid, electrolyte, and acid-base homeostasis, while promoting systemic inflammation, accelerated cardiovascular calcification, and protein-energy wasting (PEW). For the renal dietitian, mastering diagnostic definitions, underlying etiologies, and risk classification frameworks is essential for establishing timely nutritional interventions and disease surveillance.

---

Formal Clinical Definition of CKD

According to the international Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines, Chronic Kidney Disease is defined as abnormalities of kidney structure or function, present for greater than three (> 3) months, with implications for health. The requirement of a 3-month duration distinguishes chronic, irreversible nephron remodeling from reversible acute kidney injury (AKI) or subacute acute kidney diseases and disorders (AKD).

                  Diagnostic Criteria for Chronic Kidney Disease
  ══════════════════════════════════════════════════════════════════════════
   A patient qualifies for the diagnosis of CKD if EITHER criterion is
   sustained for a duration exceeding three (> 3) months:
  ──────────────────────────────────────────────────────────────────────────
   CRITERION 1: Decreased Glomerular Filtration Rate
   • GFR < 60 mL/min/1.73 m² (GFR categories G3a, G3b, G4, or G5)
  ──────────────────────────────────────────────────────────────────────────
   CRITERION 2: One or More Objective Markers of Kidney Damage
   • Albuminuria: AER ≥ 30 mg/24 hours OR spot UACR ≥ 30 mg/g (≥ 3 mg/mmol)
   • Urine sediment abnormalities: Dysmorphic RBCs, RBC casts, WBC casts
   • Tubular disorders: Renal tubular acidosis, Fanconi syndrome, cystinuria
   • Histological abnormalities: Glomerulosclerosis, interstitial fibrosis
   • Structural abnormalities on imaging: Polycystic kidneys, hydronephrosis,
     cortical thinning, renal artery stenosis
   • History of kidney transplantation: Documented allograft status
  ══════════════════════════════════════════════════════════════════════════

Notably, a patient with a normal or elevated GFR (e.g., $95\text{ mL/min/1.73 m}^2$) meets the formal diagnostic criteria for CKD Stage G1 if persistent albuminuria (UACR $\ge 30\text{ mg/g}$) or structural abnormalities (such as polycystic kidneys) are present for $> 3$ months.

---

Primary Etiologies of CKD in the United States

Nephron loss in CKD is initiated by systemic diseases, genetic mutations, autoimmune attacks, or primary structural insults. In the United States, data from the United States Renal Data System (USRDS) demonstrate that two primary conditions drive more than 70% of incident kidney failure:

The KDIGO 2D Staging System: The CGA Classification

Historical staging systems (such as the KDOQI 2002 guidelines) relied exclusively on GFR strata, overlooking the profound prognostic impact of albuminuria. To resolve this limitation, KDIGO established the comprehensive Cause-GFR-Albuminuria (CGA) staging matrix:

1. C - Cause: Identification of underlying etiology (e.g., Type 2 Diabetes, Hypertensive Nephrosclerosis, IgA Nephropathy).
2. G - GFR Category: Staging based on confirmed glomerular filtration rate.
3. A - Albuminuria Category: Staging based on confirmed urine albumin-to-creatinine ratio (UACR).

GFR Categories (G1 to G5)

Stage G3 is divided into G3a (45–59 mL/min/1.73 m²) and G3b (30–44 mL/min/1.73 m²) because clinical outcomes diverge sharply at an eGFR of 45 mL/min/1.73 m². Patients entering G3b experience an exponential increase in cardiovascular mortality, hyperparathyroidism, metabolic acidosis, anemia, and rate of progression to kidney failure compared to those in G3a.

Albuminuria Categories (A1 to A3)

Albuminuria is measured preferably on an early-morning spot urine sample expressed as the urine albumin-to-creatinine ratio (UACR), which corrects for variations in urinary concentration:

---

The KDIGO 2D Risk Heat Map

The intersection of GFR and Albuminuria categories generates a two-dimensional prognosis matrix that predicts four major clinical endpoints:

1. CKD progression (rate of GFR loss and time to kidney failure)
2. All-cause mortality
3. Cardiovascular mortality
4. Acute Kidney Injury (AKI) episodes

                    KDIGO 2D Progression & Mortality Risk Grid
  ┌───────────────┬──────────────────────┬──────────────────────┬──────────────────────┐
  │ GFR Category  │   A1: Normal/Mild    │    A2: Moderately    │     A3: Severely     │
  │ (mL/min/1.73) │     (< 30 mg/g)      │    (30–300 mg/g)     │     (> 300 mg/g)     │
  ├───────────────┼──────────────────────┼──────────────────────┼──────────────────────┤
  │ G1 (≥ 90)     │      LOW RISK        │   MODERATE RISK      │      HIGH RISK       │
  │               │      (Green)         │      (Yellow)        │       (Orange)       │
  ├───────────────┼──────────────────────┼──────────────────────┼──────────────────────┤
  │ G2 (60–89)    │      LOW RISK        │   MODERATE RISK      │      HIGH RISK       │
  │               │      (Green)         │      (Yellow)        │       (Orange)       │
  ├───────────────┼──────────────────────┼──────────────────────┼──────────────────────┤
  │ G3a (45–59)   │   MODERATE RISK      │      HIGH RISK       │    VERY HIGH RISK    │
  │               │      (Yellow)        │       (Orange)       │        (Red)         │
  ├───────────────┼──────────────────────┼──────────────────────┼──────────────────────┤
  │ G3b (30–44)   │      HIGH RISK       │    VERY HIGH RISK    │    VERY HIGH RISK    │
  │               │       (Orange)       │        (Red)         │        (Red)         │
  ├───────────────┼──────────────────────┼──────────────────────┼──────────────────────┤
  │ G4 (15–29)    │    VERY HIGH RISK    │    VERY HIGH RISK    │    VERY HIGH RISK    │
  │               │        (Red)         │        (Red)         │        (Red)         │
  ├───────────────┼──────────────────────┼──────────────────────┼──────────────────────┤
  │ G5 (< 15)     │    VERY HIGH RISK    │    VERY HIGH RISK    │    VERY HIGH RISK    │
  │               │        (Red)         │        (Red)         │        (Red)         │
  └───────────────┴──────────────────────┴──────────────────────┴──────────────────────┘

Clinical Implications of the Heat Map

A critical takeaway from the KDIGO heat map is that albuminuria confers risk independent of GFR. For example, a patient with Stage G1 or G2 who displays severely increased albuminuria (A3, $>300$ mg/g) carries a higher cardiovascular mortality and CKD progression risk (Orange, High Risk) than a patient with Stage G3a and normal albuminuria (Yellow, Moderate Risk).

Similarly, when a patient with Stage G3a progresses from A1 to A3, their risk tier escalates directly from Moderate Risk (Yellow) to Very High Risk (Red). Consequently, nutrition measures that lower intraglomerular pressure and albuminuria matter at every stage: sodium restriction (KDOQI 2020: below 2.3 g/day; KDIGO 2024: below 2 g/day) and moderated protein intake (KDOQI 2020: 0.55–0.60 g/kg/day for stable CKD 3–5 without diabetes; KDIGO 2024: 0.8 g/kg/day, avoiding more than 1.3 g/kg/day) complement RAAS blockade and SGLT2 inhibitors.

---

Evolution of GFR Estimating Equations

Accurate assessment of GFR is necessary for staging CKD, monitoring disease trajectory, adjusting medication dosages, and formulating protein and electrolyte prescriptions. True GFR can be directly measured via urinary clearance of exogenous filtration markers such as inulin, iohexol, or $^{125}\text{I}$-iothalamate. However, because continuous infusions and timed urinary collections are cumbersome, clinical practice relies on mathematical equations utilizing endogenous filtration biomarkers.

1. The Cockcroft-Gault Equation (1976)

Developed by Donald Cockcroft and Henry Gault, this historic formula estimates creatinine clearance ($eC_{cr}$) rather than true GFR:

$eC_{cr} \text{ (mL/min)} = \frac{(140 - \text{age}) \times \text{actual body weight (kg)}}{72 \times \text{serum creatinine (mg/dL)}} \times (0.85 \text{ if female})$

Key Limitations:

• Estimates creatinine clearance, which inherently overestimates true GFR by 10% to 20% because creatinine undergoes active proximal tubular secretion via organic cation transporter 2 (OCT2) in addition to glomerular ultrafiltration.
• Incorporates body weight directly into the numerator without indexing for body surface area ($1.73\text{ m}^2$). In obese patients or individuals with profound fluid overload/edema, actual body weight artifactually inflates estimated clearance.
• Highly vulnerable to errors in patients with sarcopenia or limb amputations.
• Exam Relevance: Cockcroft-Gault is no longer recommended for clinical CKD staging, but candidates must recognize it because many legacy FDA-approved pharmaceutical drug labels still reference Cockcroft-Gault thresholds for renal drug adjustments.

2. The MDRD Study Equation (1999/2006)

The Modification of Diet in Renal Disease (MDRD) 4-variable equation indexed values to $1.73\text{ m}^2$ BSA and eliminated the need for body weight by incorporating serum creatinine, age, sex, and race. However, because it was derived entirely from patients with established CKD, the MDRD equation systematically underestimated GFR at normal or mildly reduced levels ($> 60\text{ mL/min/1.73 m}^2$), producing high false-positive rates for CKD Stage G3a in healthy individuals.

3. The CKD-EPI 2021 Race-Free Creatinine Equation

In 2021, the National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Diseases recommended the immediate nationwide adoption of the 2021 CKD-EPI race-free creatinine equation.

This equation was refit without the historical race adjustment variable to ensure equitable clinical staging, kidney transplant waitlist accession, and nutritional guidance. It provides superior diagnostic accuracy across the full range of kidney function compared to the 2009 equation and the MDRD formula.

$\text{eGFR}_{\text{cr(2021)}} = 142 \times \min(S_{cr}/\kappa, 1)^{\alpha} \times \max(S_{cr}/\kappa, 1)^{-1.200} \times 0.9938^{\text{Age}} \times [1.012 \text{ if female}]$ (Where $\kappa = 0.7$ for females, $0.9$ for males; $\alpha = -0.241$ for females, $-0.302$ for males; $S_{cr}$ is serum creatinine in mg/dL).

---

Serum Cystatin C & Combined Equations: The Gold Standard Confirmatory Biomarker

While serum creatinine remains the primary first-line biomarker for GFR estimation, it possesses major clinical confounders because creatinine is an endogenous breakdown product of creatine and phosphocreatine in skeletal muscle. Consequently, serum creatinine is heavily dependent on total muscle mass, physical activity, dietary meat intake, and tubular secretion.

Limitations of Creatinine in Clinical Practice

• Sarcopenia & Muscle Wasting: In patients with severe protein-energy wasting, spinal cord injury, or limb amputations, creatinine generation is profoundly reduced. Serum creatinine may remain within the normal range ($0.7–0.9$ mg/dL) despite a true GFR $< 30$ mL/min/1.73 m², severely underestimating the severity of CKD.
• Dietary Meat Consumption: Cooked red meat contains exogenous creatinine. Consuming large meat meals acutely elevates serum creatinine, creating transient artifacts in eGFR.
• Medications Inhibiting Tubular Secretion: Trimethoprim, cimetidine, cobicistat, and dolutegravir inhibit OCT2-mediated tubular creatinine secretion, raising serum creatinine by 0.2 to 0.4 mg/dL without affecting true GFR.

Serum Cystatin C

Cystatin C is a low-molecular-weight (13.3 kDa) non-glycosylated basic protein belonging to the cystatin superfamily of cysteine protease inhibitors. It is produced by all nucleated cells at a constant, constitutive rate:

                      Serum Creatinine vs. Serum Cystatin C
  ═══════════════════════════════════════════════════════════════════════════
   Physiologic Property      Serum Creatinine         Serum Cystatin C
  ───────────────────────────────────────────────────────────────────────────
   Molecular Weight          113 Daltons              13,300 Daltons (13.3 kDa)
   Source of Generation      Skeletal muscle creatine Constantly produced by
                             breakdown & cooked meat  all nucleated cells
   Muscle Mass Dependent     YES (Profoundly)         NO (Completely independent)
   Dietary Intake Dependent  YES (High meat meals)    NO (Independent of diet)
   Tubular Handling          Glomerular filtration +  Glomerular filtration +
                             10–20% tubular secretion Complete tubular uptake
                                                      and catabolism (no secretion)
   Confirmatory Role         Initial screening test   Standard confirmatory test
  ═══════════════════════════════════════════════════════════════════════════

Because cystatin C is completely cleared by glomerular filtration and then completely reabsorbed and metabolized by proximal tubular epithelial cells without tubular secretion, its serum concentration is determined almost exclusively by GFR.

Clinical Indications for Cystatin C Testing

KDIGO guidelines recommend obtaining a serum cystatin C test and calculating the CKD-EPI 2021 Creatinine-Cystatin C combined equation ($\text{eGFR}_{\text{cr-cys}}$) in the following clinical scenarios:

1. Confirming CKD Stage G3a: When eGFR based on creatinine is 45–59 mL/min/1.73 m² in an individual without markers of kidney damage (A1 albuminuria). If the cystatin C-based eGFR is $\ge 60$ mL/min/1.73 m², the diagnosis of CKD is refuted.
2. Altered Body Composition & Extreme Sarcopenia: In cirrhotic patients, quadriplegic/paraplegic patients, individuals with bilateral amputations, and patients with severe protein-energy wasting (PEW) on dialysis.
3. Extreme Dietary Patterns: Strict vegans or individuals consuming massive creatine supplements or high-protein meat diets.
4. High-Accuracy Needs: Precisely timing vascular access placement, dialytic therapy initiation, or kidney transplant waitlisting.